Larvol Delta - US-FDA-Grants-to-Wugens-WUCART007-Breakthrough-Therapy-Designation-for-Treatment-of-Relapsed-or-Refractory-T-Cell-Acute-Lymphoblastic-Leukemia--T-Cell-Lymphoblastic-Lymphoma

soficabtagene geleucel (WU CART 007) - Wugen

https://www.businesswire.com/news/home/20260121930614/en/U.S.-FDA-Grants-to-Wugens-WU-CART-007-Breakthrough-Therapy-Designation-for-Treatment-of-Relapsed-or-Refractory-T-Cell-Acute-Lymphoblastic-Leukemia-T-Cell-Lymphoblastic-Lymphoma

Jan 21, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next